Achievements and unmet needs in the management of advanced ovarian cancer

Gynecologic Oncology

Volumn 117, Issue 2, 2010, Pages 152-158

  Guarneri, Valentina ^a   Piacentini, Federico ^a   Barbieri, Elena ^a   Conte, Pier Franco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cytoreductive surgery; First line chemotherapy; Intraperitoneal chemotherapy; Maintenance therapy; Ovarian cancer; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; ETOPOSIDE; GEFITINIB; GEMCITABINE; IMATINIB; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MUCIN 1; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; OREGOVOMAB; PACLITAXEL; PACLITAXEL POLIGLUMEX; TANOMASTAT; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CATHETER COMPLICATION; CHEMOSENSITIVITY; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPHADENECTOMY; MAINTENANCE THERAPY; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS; SALVAGE THERAPY;

EID: 77950188167     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.033     Document Type: Review

References (105)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18 3 (2007) 581-592
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics 2008. C.A. Cancer J. Clin. 58 (2008) 71-96
3. Bell R., Pettierew M., Luengo S., and Sheldon T.A. Screening for ovarian cancer: a systematic review. Health Technol. Assess. 2 (1998) 1-84
4. Omura G.A., Brady M.F., Homesley H.D., et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol. 9 (1991) 1138-1150
5. van Houwelingen J.C., ten Bokkel Huinink W.W., van der Burg M.E., et al. Predictability of the survival of patients with advanced ovarian cancer. J. Clin. Oncol. 7 (1989) 769-773
6. Thigpen T., Brady M.F., Omura G.A., et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 71 (1993) 606-614
7. Meigs J.V. Tumors of the female pelvic organs (1934), MacMillan, New York
8. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 42 (1975) 101-104
9. Allen D.G., Heintz A.P., and Touw F.W. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur. J. Gynaecol. Oncol. 16 (1995) 349-356
10. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
11. Panici P.B., Maggioni A., Hacker N., Landoni F., Ackermann S., Campagnutta E., et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J. Natl. Cancer Inst. 97 (2005) 560-566
12. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 98 (2006) 172-180
13. Vernooij F., Heintz P., Witteveen E., and van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol. Oncol. 105 (2007) 801-812
14. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.L., van Oostrom A.T., Willemse P.H.B., Heintz A.P.M., et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J. Clin. Oncol. 5 (1987) 1157-1168
15. Wils J., Blijham G., Naus A., Belder C., Boschma F., Bron H., et al. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J. Clin. Oncol. 4 (1986) 1068-1073
16. Lawton F., Luesley D., Redman C., Chan K.K., Varma R., and Blackledge G. Feasibility and outcome of complete secondary tumor resection for patients with advanced ovarian cancer. J. Surg. Oncol. 45 (1990) 14-19
17. Lawton F.G., Redman C.W.E., Luesley D.M., Chan K.K., and Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet. Gynecol. 73 (1989) 61-65
18. Redman C.W.E., Blackledge G., Lawton F.G., Varma R., Luesley D.M., and Chan K.K. Early second surgery in ovarian cancer-improving the potential for cure or another unnecessary operation. Eur. J. Surg. Oncol. 16 (1990) 426-429
19. Jacob J.H., Gershenson D.M., Morris M., Copeland L.J., Burke T.W., and Wharton J.T. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 42 (1991) 146-150
20. Redman C.W.E., Warwick J., Luesley D.M., Varman R., Lawton F.G., and Blackledge G.R.P. Intervention debulking surgery in advanced epithelial ovarian cancer. Br. J. Obstet. Gynecol. 101 (1994) 142-146
21. van der Burg M.E.L., van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis of advanced epithelial ovarian cancer. N. Engl. J. Med. 332 (1995) 629-634
22. Rose P.G., Nerenstone S., Brady M.F., Clarke-Pearson D., Olt G., Rubin S.C., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med. 351 (2004) 2489-2497
23. Bristow E.R., and Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol. Oncol. 103 (2006) 1070-1076
24. Vergote I., van Gorp T., Amant F., Leunen K., Neven P., and Berteloot P. Timing of debulking surgery in advanced ovarian cancer. Int. J. Gynecol. Cancer 18 (2008) 11-19
25. Omura G., Blassing J.A., Ehrlich C.E., Miller A., Yordan E., Creasman W.T., et al. randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer 57 (1986) 1725-1730
26. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.E., van Oosterom A.T., Vriesendorp R., Kooyman C.D., et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 2 (1984) 594-600
27. Alberts D.S., Green S., Hannigan E.V., O'Toole R., Stock-Novack D., Anderson P., et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III study randomized trial in stages III and IV ovarian cancer. J. Clin. Oncol. 10 (1992) 706-717
28. Swenerton K., Jeffrey J., Stuart G., Roy M., Krepart G., Carmichael J., et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 10 (1992) 718-726
29. Gurney H., Crowther D., Andersen H., Murphy D., Prendiville J., Ranson M., et al. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Ann. Oncol. 1 (1990) 427-433
30. Conte P.F., Bruzzone M., Carnino F., Chiara S., Donadio M., Facchini V., et al. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. J. Clin. Oncol. 9 (1991) 658-663
31. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br. Med. J. 303 (1991) 884-893
32. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
33. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92 (2000) 699-708
34. Piccart M.J., Bertelsen K., Stuart G., Cassidy J., Mangioni C., Simonsen E., et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int. J. Gynecol. Cancer 13 Suppl 2 (2003) 144-148
35. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 18 (2000) 106-115
36. ICON. International Collaborative Ovarian Neoplasm Study. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360 (2002) 505-515
37. Sandercock J., Parmar M.K., Torri V., and Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br. J. Cancer 87 (2002) 815-824
38. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III Ovarian Cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 21 (2003) 3194-3200
39. Du Bois A., Lück H.J., Meier W., Adams H.P., Möbus V., Costa S., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 1320-1330
40. Bertelsen K., Jacobsen A., Andersen E., Ahrons S., Pedersen P.H., Kiaer H., et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian cancer. Gynecol. Oncol. 28 (1987) 161-169
41. Gruppo Interregionale Cooperativo Oncologico Ginecologia (GICOG). Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. Gynecol. Oncol. 45 (1992) 115-117
42. Gadducci A., Bruzzone M., Carnino F., Ragni N., Rubagotti A., and Conte P.F. Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer 6 (1996) 286-290
43. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide, doxorubicin, and cisplatin chemotherapy for ovarian carcinoma: a meta-analysis. J. Clin. Oncol. 9 (1991) 1668-1674
44. A'Hern R.P., and Gore M.E. Impact of doxorubicin on survival in advanced ovarian cancer. J. Clin. Oncol. 45 (1995) 726-732
45. Fanning J., Bennett T.Z., and Hilgers R.D. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet. Gynecol. 80 (1992) 954-960
46. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 352 (1998) 1571-1576
47. du Bois A., Weber B., Rochon J., Meier W., Goupil A., Olbricht S., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynaecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J. Clin. Oncol. 24 (2006) 1127-1135
48. Aravantinos G., Fountzilas G., Bamias A., Grimani I., Rizos S., Kalofonos H.P., et al. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur. J. Cancer 44 (2008) 2169-2177
49. Bookman M.A., Brady M.F., McGuire W.P., Harper P.G., Alberts D.S., Friedlander M., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27 9 (2009 Mar 20) 1419-1425
50. Pignata S., Scambia G., Savarese A., Breda E., Sorio R., Pisano C., et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology 76 (2009) 49-54
51. Isonishi S., Yasuda M., Takahashi F., Katsumata N., Kimura E., Aoki T., et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J. Clin. Oncol. 26 15suppl (2008) 294s (abstract 5506)
52. Howell S.B., Pfeifle C.L., Wung W.E., Olshen R.A., Lucas W.E., Yon J.L., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97 (1982) 845-851
53. Zylberberg B., Ravina J.H., Salat-Baroux J., Dormont D., Lipp B., and Guillet J.L. Polychemotherapy of ovarian cancer via combined intravenous and intraperitoneal routes. Technic and preliminary results. J. Gynecol. Obstet. Biol. Reprod. 15 (1986) 671-676
54. Polyzos A., Tsavaris N., Kosmas C., Giannikos L., Katsikas M., Kalahanis N., et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 56 (1999) 291-296
55. Kirmani S., Braly P.S., McClay E.F., Saltzstein S.L., Plaxe S.C., Kim S., et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol. Oncol. 54 (1994) 338-344
56. Gadducci A., Carnino F., Chiara S., Brunetti I., Tanganelli L., Romanini A., et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol. Oncol. 76 (2000) 157-162
57. Yen M.S., Juang C.M., Lai C.R., Chao G.C., Ng H.T., and Yuan C.C. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int. J. Gynaecol. Obstet. 72 (2001) 55-60
58. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 26 (1996) 1950-1955
59. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
60. Armstrong D.K., Bundy B., Wenzel L., Huang H.E., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
61. Jaaback K., and Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst. Rev. 1 (2006) CD005340
62. Elit L., Oliver T.K., Covens A., Kwon J., Fung M.F., Hirte H.W., et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 109 (2007) 692-702
63. Gadducci A., and Conte P.F. Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. Int. J. Gynecol. Cancer 18 (2008) 943-953
64. Neijt J.P., Engelholm S.A., Tuxen M.K., orensen P.G., Hansen M., Sessa C., et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18 (2000) 3084-3092
65. Gadducci A., Sartori E., Maggino T., Zola P., Landoni F., Fanucchi A., et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol. Oncol. 68 (1998) 150-155
66. Gadducci A., Cosio S., Conte P.F., and Gennazzani A.R. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit. Rev. Oncol. Hematol. 55 (2005) 153-166
67. Bruzzone M., Repetto L., Chiara S., Campora E., Conte P.F., Orsatti M., et al. Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol. Oncol. 38 (1990) 392-395
68. Sorbe B., and Swedish-Norwegian Ovarian Cancer Study Group. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int. J. Gynecol. Cancer 13 (2003) 278-286
69. Varia M.A., Stehman F.B., Bundy B.N., Benda J.A., Clarke-Pearson D.L., Alvarez R.D., et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21 (2003) 2849-2855
70. Verheijen R.H., Massuger L.F., Benigno B.B., Epenetos A.A., Lopes A., Soper J.T., et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24 (2006) 571-578
71. Hall G.D., Brown J.M., Coleman R.E., Stead M., Metcalf K.S., Peel K.R., et al. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br. J. Cancer 91 (2004) 621-626
72. Hirte H., Vergote I.B., Jeffrey J.R., Grimshaw R.N., Coppieters S., Schwartz B., et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol. Oncol. 102 (2006) 300-308
73. Berek J., Taylor P., McGuire W., Smith L.M., Schultes B., and Nicodemus C.F. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol. 27 (2009) 418-425
74. Piccart M.J., Floquet A., Scarfone G., Willemse P.H., Emerich J., Vergote I., et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer 13 suppl 2 (2003) 196-203
75. Cure H., Battista C., Guastalla J.P., Fabbro M., Tubiana N., Bourgeois H., et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Proc. Am. Soc. Clin. Oncol. 23 (2004) 449 (abstr 5006)
76. Papadimitriou C., Dafni U., Anagnostopoulos A., Vlachos G., Voulgaris Z., Rodolakis A., et al. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. Bone Marrow Transplant. 41 (2008) 547-554
77. Bolis G., Danese S., Tateo S., Rabaiotti E., D'Agostino G., Merisio C., et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 74-78
78. De Placido S., Scambia G., Di Vagno G., Naglieri E., Vernaglia Lombardi A., Biamonte R., et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J. Clin. Oncol. 22 (2004) 2635-2642
79. Pfisterer J., Weber B., Reuss A., Kimming R., du Bois A., Wagner U., et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl. Cancer Inst. 98 (2006) 1036-1045
80. Hakes T.B., Chalas E., Hoskins W.J., Jones W.B., Markman M., Rubin S.C., et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol. Oncol. 45 (1992) 284-289
81. Bertelsen K., Jakobsen A., Stroyer J., Nielsen K., Sandberg E., Andersen J.E., et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol. Oncol. 49 (1993) 30-36
82. Lambert H.E., Rustin G.J., Gregory W.M., and Nelstrop A.E. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann. Oncol. 8 (1997) 327-333
83. Markman M., Liu P.Y., Wilczynski S., Monk B., Copeland L.J., Alvarez R.D., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21 (2003) 2460-2465
84. 2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol. Oncol. 114 (2009) 195-198
85. Pecorelli S., Favalli G., Gadducci A., Katsaros D., Benedetti Panici P., Carpi A., et al. Final results of After-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel in advanced epithelial ovarian cancer patients in complete response after 6 courses of paclitaxel/platinum-based chemotherapy. J. Clin. Oncol. 27 (2009) 4642-4648
86. Markman M. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol. Sci. 29 (2008) 515-519
87. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR2.2 trial. Lancet 361 (2003) 2099-2106
88. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24 (2006) 4699-4707
89. Gordon A.N., Tonda M., Sun S., et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 95 (2004) 1-8
90. Ten Bokkel Huinink W.W., Sufliarsky J., Smit W.M., Spanik S., Wagnerova M., Hirte H.W., et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J. Clin. Oncol. 27 (2009) 3097-3103
91. Rustin G.J., an der Burg M.E., and on behalf of MRC and EORTC collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J. Clin. Oncol. 27 (2009) 18s (suppl; abstr 1)
92. Sabbatini P., and Odunsi K. Immunologic approaches to ovarian cancer. J. Clin. Oncol. 25 (2007) 2884-2893
93. Bookman M.A., darcy K.M., Clarke-Pearson D., Boothby R.A., and Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21 (2003) 283-290
94. Schilder R.J., Sill M.W., Chen X., Darcy K.M., Decesare S.L., Lewandowski G., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11 (2005) 5539-5548
95. Coleman R.L., Broaddus R.R., Bodurka D.C., Wolf J.K., Burke T.W., Kavanagh J.J., et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol. Oncol. 101 (2006) 126-131
96. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25 (2007) 5165-5171
97. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
98. Audeh M.W., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol. 27 (2009) 15s (suppl; abstr 5500)
99. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361 (2009) 123-134
100. Turner N., Tutt A., and Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4 (2004) 814-819
101. Tan D.S., Rothermundt C., Thomas K., Bancroft E., Eeles R., Shanley S., et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 26 (2008) 5530-5536
102. Jacinto F.V., and Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 22 (2007) 247-253
103. Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10 (2009) 327-340
104. Yap T.A., Carden C.P., and Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 9 (2009) 167-181
105. Collison F., and Jayson G. New therapeutic agents in ovarian cancer. Curr. Opin. Obstet. Gynecol. 21 (2009) 44-53